Effect of Efpeglenatide on Cardiovascular Outcomes
Terminated · Phase 3 · NCT03496298
Conditions: Type 2 Diabetes Mellitus
At a glance
- Research payments reported, 2025
- $514
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 4,076
About the trial
- Sponsor
- Sanofi (with Hanmi Pharmaceutical Company Limited)
- Tested
- Efpeglenatide (SAR439977) (drug), Placebo (drug)
- Dates
- Started 2018-04-27; completion 2020-12-10
- Results posted
- Yes
Primary Objective: To demonstrate that efpeglenatide 4 and 6 mg was noninferior to placebo on 3-point major adverse cardiac events (MACE) in Type 2 diabetes mellitus (T2DM) participants at high cardiovascular (CV) risk. Secondary Objectives: To demonstrate that efpeglenatide 4 and 6 mg was superior to placebo in T2DM participants with high CV risk on the following parameters: * 3-point MACE. * Expanded CV outcome. * Composite outcome of new or worsening nephropathy. To assess the safety and tolerability of efpeglenatide 4 and 6 mg, both added to standard of care in T2DM participants at high CV risk.
From ClinicalTrials.gov, last updated 2021-10-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $514 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Arcturus Healthcare,plc Troy Internal Medicine Research Divide $514
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.